Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683349 | 0.77 | — | — | |
| SCHEMBL18857346 | 0.73 | — | — | |
| SCHEMBL2616427 | 0.73 | LMNA (0.33) | CYP3A4LMNAPKM | |
| SCHEMBL19274689 | 0.73 | — | — | |
| SCHEMBL13359772 | 0.70 | CYP3A4 (0.33) | CYP3A4LMNAPKM | |
| SCHEMBL13180200 | 0.70 | CYP3A4 (0.32) | CYP3A4LMNAPKM | |
| SCHEMBL6358216 | 0.67 | — | — | |
| SCHEMBL13094075 | 0.67 | LMNA (0.32) | LMNAPKM | |
| SCHEMBL13094068 | 0.67 | LMNA (0.32) | LMNAPKM | |
| SCHEMBL13010810 | 0.67 | LMNA (0.32) | LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CYP3A4 2687/4885LMNA 4876/4885PKM 3910/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | CYP3A4 2491/4885LMNA 4007/4885PKM 3734/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CYP3A4 2687/4885LMNA 4876/4885PKM 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.